Target Name: GFER
NCBI ID: G2671
Review Report on GFER Target / Biomarker Content of Review Report on GFER Target / Biomarker
GFER
Other Name(s): erv1-like growth factor | MMCHD | ERV1 | Hepatopoietin protein | HERV1 | HPO2 | ERV1 homolog | ALR_HUMAN | ALR | Erv1-like growth factor | MPMCD | Growth factor, augmenter of liver regeneration | FAD-linked sulfhydryl oxidase ALR | Hepatic regenerative stimulation substance | Truncated augmenter of liver regeneration | Augmenter of liver regeneration | hepatopoietin protein | HPO1 | HSS | HPO | hepatic regenerative stimulation substance | hERV1 | growth factor, augmenter of liver regeneration | Hepatopoietin

GERMIC For Growth and Differentiation: Unlocking the Potential of Extracellular matrix Proteins

Introduction

Growth and differentiation are two critical processes in development and maintenance of tissues, organs, and organs. These processes are tightly regulated, and a balance between them is essential for the proper functioning of the organism. One of the key factors in these processes is the extracellular matrix (ECM), which is a complex matrix of proteins, nucleic acids, and other bioactive molecules that surround and support cells. GERMIC, or Growth and Differentiation-Regulated Matrix Inhibitor, is a protein that is expressed in various tissues and cells and plays a critical role in regulating the balance between growth and differentiation.

GERMIC: A Drug Target and Biomarker

GERMIC is a member of the transforming growth factor family, which includes several proteins that are involved in cell growth, differentiation, and repair. The transforming growth factor family has been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. GERMIC is specifically targeted as a drug target due to its unique structure and its involvement in regulating the balance between growth and differentiation.

GERMIC functions as a negative regulator of the transforming growth factor pathway. It binds to the receptor tyrosine kinase (RTK), which is a key enzyme involved in the transforming growth factor signaling pathway. By binding to RTK, GERMIC inhibits the activity of several transcription factors that are involved in promoting cell growth and differentiation. This inhibition of cell growth and differentiation allows for a balance between growth and differentiation, which is essential for proper tissue development and maintenance.

GERMIC has been shown to be involved in several biological processes, including cell proliferation, differentiation, and migration. For example, GERMIC has been shown to be involved in the regulation of cell cycle progression, where it promotes the G1 phase and inhibits the S phase . Additionally, GERMIC has been shown to play a role in the regulation of cell differentiation, where it promotes the transition from a pro-inflammatory state to an anti-inflammatory state.

GERMIC has also been shown to be involved in several diseases, including cancer and neurodegenerative diseases. For example, GERMIC has been shown to be involved in the regulation of cancer cell growth and has been used as a potential therapeutic agent against several types of cancer. Additionally, GERMIC has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Targeting GERMIC: A Potential Approach

GERMIC is a protein that has not yet been fully targeted as a drug. However, several studies have identified potential drug targets for GERMIC, including the inhibition of its activity by small molecules and antibodies, and the use of small molecules and antibodies to block its interaction with RTK.

One approach to targeting GERMIC is the inhibition of its activity by small molecules. Several studies have shown that small molecules can be used to inhibit the activity of GERMIC, including inhibitors of the RTK, such as tyrosine, which is a potent inhibitor of RTK and has been shown to be involved in the regulation of GERMIC activity. Additionally, small molecules such as FAK inhibitors, which are involved in the regulation of cell adhesion, have also been shown to be inhibitors of GERMIC activity.

Another approach to targeting GERMIC is the use of antibodies to block its interaction with RTK. Several studies have shown that antibodies can be used to block the interaction between GERMIC and RTK, including antibodies that specifically recognize and inhibit the activity of GERMIC. Additionally, antibodies that recognize and block the activity of

Protein Name: Growth Factor, Augmenter Of Liver Regeneration

Functions: FAD-dependent sulfhydryl oxidase that regenerates the redox-active disulfide bonds in CHCHD4/MIA40, a chaperone essential for disulfide bond formation and protein folding in the mitochondrial intermembrane space. The reduced form of CHCHD4/MIA40 forms a transient intermolecular disulfide bridge with GFER/ERV1, resulting in regeneration of the essential disulfide bonds in CHCHD4/MIA40, while GFER/ERV1 becomes re-oxidized by donating electrons to cytochrome c or molecular oxygen

The "GFER Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GFER comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GFI1 | GFI1B | GFM1 | GFM2 | GFOD1 | GFOD2 | GFPT1 | GFPT2 | GFRA1 | GFRA2 | GFRA3 | GFRA4 | GFRAL | GFUS | GGA1 | GGA2 | GGA3 | GGACT | GGCT | GGCX | GGH | GGN | GGNBP1 | GGNBP2 | GGPS1 | GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3